Cargando…

Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer

Castration-resistant prostate cancer (CRPC) is defined by resistance of the tumor to androgen deprivation therapy (ADT). Several molecular changes, particularly in the AR signaling cascade, have been described that may explain ADT resistance. The variety of changes may also explain why the response...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamid, Agus Rizal A. H., Luna-Velez, Maria V., Dudek, Aleksandra M., Jansen, Cornelius F. J., Smit, Frank, Aalders, Tilly W., Verhaegh, Gerald W., Schaafsma, Ewout, Sedelaar, John P. M., Schalken, Jack A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417043/ https://www.ncbi.nlm.nih.gov/pubmed/34490120 http://dx.doi.org/10.3389/fonc.2021.721659

Ejemplares similares

Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy
por: Armandari, Inna, et al.
Publicado: (2014)

Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis
por: Luna Velez, Maria V., et al.
Publicado: (2019)

Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer
por: Rönnau, C. G. H., et al.
Publicado: (2021)

Delivery of antisense oligonucleotides for splice‐correction of androgen receptor pre‐mRNA in castration‐resistant prostate cancer models using cell‐penetrating peptides
por: Luna Velez, Maria V., et al.
Publicado: (2022)

Label retention and stem cell marker expression in the developing and adult prostate identifies basal and luminal epithelial stem cell subpopulations
por: Ceder, Jens Adam, et al.
Publicado: (2017)

Androgen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder
por: Luna‐Velez, Maria V., et al.
Publicado: (2021)

Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer
por: Groen, Levi, et al.
Publicado: (2023)

Noncoding RNAs as Novel Biomarkers in Prostate Cancer
por: Rönnau, C. G. H., et al.
Publicado: (2014)

The need for a personalized approach for prostate cancer management
por: Sedelaar, JP Michiel, et al.
Publicado: (2015)

Personalized Management in Low-Risk Prostate Cancer: The Role of Biomarkers
por: Dijkstra, Siebren, et al.
Publicado: (2012)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Boerrigter, Emmy, et al.
Publicado: (2021)

Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line abiraterone acetate and prednisone treatment
por: Boerrigter, Emmy, et al.
Publicado: (2021)

The Androgen Regulated lncRNA NAALADL2-AS2 Promotes Tumor Cell Survival in Prostate Cancer
por: Groen, Levi, et al.
Publicado: (2022)

A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate Cancer
por: Isebia, Khrystany T., et al.
Publicado: (2023)

Novel non-AR therapeutic targets in castrate resistant prostate cancer
por: Toren, Paul J., et al.
Publicado: (2013)

Crosstalk between KIF15 and AR in castrate-resistant prostate cancers
por: Yang, Hanny, et al.
Publicado: (2022)

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
por: Li, Qiuhui, et al.
Publicado: (2018)

Emerging proteins involved in castration-resistant prostate cancer via the AR-dependent and AR-independent pathways (Review)
por: Feng, Kangle, et al.
Publicado: (2023)

Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer
por: Sugiura, Masahiro, et al.
Publicado: (2020)

Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2
por: Labaf, Maryam, et al.
Publicado: (2022)

A short-term intervention with selenium affects expression of genes implicated in the epithelial-to-mesenchymal transition in the prostate
por: Kok, Dieuwertje E.G., et al.
Publicado: (2017)

Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer()()
por: Qiao, Yuanyuan, et al.
Publicado: (2016)

Selective degradation of AR-V7 to overcome castration resistance of prostate cancer
por: Liu, Yuan, et al.
Publicado: (2021)

Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC)
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism
por: Shah, Supriya, et al.
Publicado: (2016)

Epigenetic markers in circulating cell‐free DNA as prognostic markers for survival of castration‐resistant prostate cancer patients
por: Hendriks, Rianne J., et al.
Publicado: (2018)

Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration‐resistant prostate cancer receiving abiraterone acetate: An evidence‐based case report and review of literature
por: Yausep, Oliver E., et al.
Publicado: (2019)

Crosstalk Between AR and Wnt Signaling Promotes Castration-Resistant Prostate Cancer Growth
por: Luo, Jun, et al.
Publicado: (2020)

The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
por: Zheng, Zeyuan, et al.
Publicado: (2022)

Polyisocyanide Hydrogels as a Tunable Platform for Mammary Gland Organoid Formation
por: Zhang, Ying, et al.
Publicado: (2020)

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
por: Kallio, Heini M. L., et al.
Publicado: (2018)

Early upregulation of AR and steroidogenesis enzyme expression after 3 months of androgen-deprivation therapy
por: Hamid, Agus Rizal A. H., et al.
Publicado: (2020)

AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel
por: Sieuwerts, Anieta M., et al.
Publicado: (2019)

Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer
por: Jones, Dominic, et al.
Publicado: (2017)

Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2023)

RF27 | LBSUN342 Ar-targeted Linked-read Sequencing Reveals Complex Ar Structural Variants In Castration Resistant Prostate Cancer Models
por: Zivanovic, Andrej, et al.
Publicado: (2022)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer
por: Gu, Peng, et al.
Publicado: (2019)

p38 MAPK Inhibition Mitigates Hypoxia-Induced AR Signaling in Castration-Resistant Prostate Cancer
por: Cheung, Serina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i6adth7pogs5ltjecab5bd6hqr